ArticleJournal of clinical hypertension (Greenwich, Conn.)2025
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension: A Pilot Study.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension: A Pilot Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Perirenal adipose tissue (PRAT) contributes to the maintenance of elevated blood pressure through afferent nerves and serves as an important peripheral, modifiable target for hypertension management. This single-center, prospective pilot trial assessed the feasibility and safety of a novel focused power ultrasound device for perirenal adipose tissue modification (PRATM) therapy in essential hypertension. Twenty patients (mean age 47.5 ± 11.0 years, 85% male) with office systolic blood pressure (OSBP) 140-180 mmHg or diastolic blood pressure (ODBP) ≥90 mmHg were enrolled. All underwent PRATM therapy and were followed for 3 months. The primary endpoint was all-cause mortality or device-related adverse events (AEs). Four patients experienced transient mild lumbar pain, and one had mild skin redness, all resolving spontaneously. No serious AEs or clinically significant abnormalities were observed. OSBP decreased by 14.6 mmHg at 1 month and 18.2 mmHg at 3 months; ODBP decreased by 5.8 mmHg and 2.8 mmHg, respectively. For the 24-hour ambulatory blood pressure monitoring (ABPM), 24-hour ambulatory SBP decreased by 3.6 mmHg (95% CI: -3.6-10.8 mmHg) and 24-hour ambulatory DBP decreased by 2.2 mmHg (95% CI: -2.7-7.0 mmHg) at 1 month. At 3 months, 24-hour ambulatory SBP decreased by 2.8 mmHg (95% CI: -5.4-11.0 mmHg) and 24-hour ambulatory DBP decreased by 1.7 mmHg (95% CI: -4.0-7.3 mmHg). PRATM shows preliminary feasibility and safety, but larger, randomized trials are needed for definitive efficacy and long-term safety validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.